Topic
11 articles
The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson's disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology.
Pharmacists preparing for the advent of Connecticut's medical marijuana industry gathered Wednesday to talk about the clinical aspects of dispensing a drug that has no federal approval nor the guidelines that go along with it.
Cannabidiol (CBD), a cannabinoid in marijuana, may help Parkinson’s disease sufferers overcome sleep problems, a new study from the University of Sao Paulo in Brazil has found.
Researchers believe compounds that target the body’s marijuana pathways, known as the endocannabinoid system, could lead to the development of treatments.
At Ladybud, Dianna Donnelly reports her experience battling the mythology about "Mr. T.H. Cannabinol"
Inhaling whole-plant cannabis provides symptomatic relief in patients with Parkinson’s disease (PD), according to observational trial data published in the March/April edition of the journal Clinical Neuropharmacology.
Authors reported that both animal and human studies document the ability of CBD to mitigate symptoms of psychosis.
On Tuesday, in pharmacies across the Czech Republic, medical marijuana was made available to patients suffering from cancer, Parkinson’s, MS, or psoriasis.
New York is the latest state to see medical marijuana legislation. Richard Gottfried filed Assembly Bill 6357 and Diane Savino filed Senate Bill 4406.
Massachusetts is the 18th state since 1996 to allow for the physician-authorized use of cannabis as a therapeutic option for qualified patients. It took...
One of the last, but not too unsurprising hold out demographics in America to fully embrace cannabis law reform are seniors. Here are eleven things about...
